Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Vermorken JB, Mangioni C, Pecorelli S, Van Der Burg ME, Van Oosterom AT, Ten Bokkel Huinink WW, Rotmensz N, Dalesio O.
PMID: 11240699
Int J Gynecol Cancer. 2000 Sep;10(5):358-365. doi: 10.1046/j.1525-1438.2000.010005358.x.

The objective of this study was to study the antitumor activity of the vincristine, bleomycin, mitomycin C and cisplatin (VBMP) scheme in patients with disseminated squamous cell carcinoma of the uterine cervix and to document its toxicity. VBMP consisted...

Cite
Vermorken JB, Mangioni C, Pecorelli S, et al. Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix. Int J Gynecol Cancer. 2000;10(5):358-365doi: 10.1046/j.1525-1438.2000.010005358.x.
Vermorken, J. B., Mangioni, C., Pecorelli, S., Van Der Burg, M. E., Van Oosterom, A. T., Ten Bokkel Huinink, W. W., Rotmensz, N., & Dalesio, O. (2000). Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 10(5), 358-365. https://doi.org/10.1046/j.1525-1438.2000.010005358.x
Vermorken, J. B., et al. "Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society vol. 10,5 (2000): 358-365. doi: https://doi.org/10.1046/j.1525-1438.2000.010005358.x
Vermorken JB, Mangioni C, Pecorelli S, Van Der Burg ME, Van Oosterom AT, Ten Bokkel Huinink WW, Rotmensz N, Dalesio O. Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix. Int J Gynecol Cancer. 2000 Sep;10(5):358-365. doi: 10.1046/j.1525-1438.2000.010005358.x. PMID: 11240699.
Copy Download .nbib Format: NLM
Docetaxel: a new active agent in the therapy of metastatic breast cancer.

Expert opinion on investigational drugs

Fumoleau P, Seidman AD, Trudeau ME, Chevallier B, Ten Bokkel Huinink WW.
PMID: 15989586
Expert Opin Investig Drugs. 1997 Dec;6(12):1853-65. doi: 10.1517/13543784.6.12.1853.

Breast cancer is the most common malignancy in women, accounting for about 18% of female cancers, and over half a million new cases are diagnosed worldwide each year. Its incidence increases with age and is currently rising. Although the...

Cite
Fumoleau P, Seidman AD, Trudeau ME, et al. Docetaxel: a new active agent in the therapy of metastatic breast cancer. Expert Opin Investig Drugs. 1997;6(12):1853-65doi: 10.1517/13543784.6.12.1853.
Fumoleau, P., Seidman, A. D., Trudeau, M. E., Chevallier, B., & Ten Bokkel Huinink, W. W. (1997). Docetaxel: a new active agent in the therapy of metastatic breast cancer. Expert opinion on investigational drugs, 6(12), 1853-65. https://doi.org/10.1517/13543784.6.12.1853
Fumoleau, P, et al. "Docetaxel: a new active agent in the therapy of metastatic breast cancer." Expert opinion on investigational drugs vol. 6,12 (1997): 1853-65. doi: https://doi.org/10.1517/13543784.6.12.1853
Fumoleau P, Seidman AD, Trudeau ME, Chevallier B, Ten Bokkel Huinink WW. Docetaxel: a new active agent in the therapy of metastatic breast cancer. Expert Opin Investig Drugs. 1997 Dec;6(12):1853-65. doi: 10.1517/13543784.6.12.1853. PMID: 15989586.
Copy Download .nbib Format: NLM
Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease.

European journal of gastroenterology & hepatology

Ten Bokkel Huinink S, Biemans V, Duijvestein M, Pierik M, Hoentjen F, West RL, van der Woude CJ, de Vries AC.
PMID: 34334713
Eur J Gastroenterol Hepatol. 2021 Jul 30; doi: 10.1097/MEG.0000000000002256. Epub 2021 Jul 30.

BACKGROUND AND AIM: Re-induction with intravenous ustekinumab after secondary loss of response in Crohn's disease is a relatively new strategy to regain efficacy. This real-world cohort study aimed to evaluate its effectiveness and safety.METHODS: Crohn's disease patients with loss...

Cite
Ten Bokkel Huinink S, Biemans V, Duijvestein M, et al. Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease. Eur J Gastroenterol Hepatol. 2021;doi: 10.1097/MEG.0000000000002256.
Ten Bokkel Huinink, S., Biemans, V., Duijvestein, M., Pierik, M., Hoentjen, F., West, R. L., van der Woude, C. J., & de Vries, A. C. (2021). Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease. European journal of gastroenterology & hepatology, . https://doi.org/10.1097/MEG.0000000000002256
Ten Bokkel Huinink, Sebastiaan, et al. "Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease." European journal of gastroenterology & hepatology vol. (2021). doi: https://doi.org/10.1097/MEG.0000000000002256
Ten Bokkel Huinink S, Biemans V, Duijvestein M, Pierik M, Hoentjen F, West RL, van der Woude CJ, de Vries AC. Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease. Eur J Gastroenterol Hepatol. 2021 Jul 30; doi: 10.1097/MEG.0000000000002256. Epub 2021 Jul 30. PMID: 34334713.
Copy Download .nbib Format: NLM
Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry.

European urology oncology

Kuppen MCP, Westgeest HM, van den Eertwegh AJM, van Moorselaar RJA, van Oort IM, Coenen JLLM, van den Bergh ACMF, Mehra N, Somford DM, Bergman AM, Ten Bokkel Huinink D, Fossion L, Geenen MM, Hendriks MP, van de Luijtgaarden ACM, Polee MB, Weijl NI, van de Wouw AJ, de Wit R, Uyl-de Groot CA, Gerritsen WR.
PMID: 31601523
Eur Urol Oncol. 2021 Aug;4(4):618-627. doi: 10.1016/j.euo.2019.09.005. Epub 2019 Oct 08.

BACKGROUND: Cross resistance between androgen-receptor targeting therapies (ARTs) (abiraterone acetate plus prednisone [ABI+P] or enzalutamide [ENZ]) for treatment of metastatic castration-resistant prostate cancer (mCRPC) may affect responses to second ART (ART2).OBJECTIVE: To establish treatment duration and prostate-specific antigen (PSA)...

Cite
Kuppen MCP, Westgeest HM, van den Eertwegh AJM, et al. Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. Eur Urol Oncol. 2019;4(4):618-627doi: 10.1016/j.euo.2019.09.005.
Kuppen, M. C. P., Westgeest, H. M., van den Eertwegh, A. J. M., van Moorselaar, R. J. A., van Oort, I. M., Coenen, J. L. L. M., van den Bergh, A. C. M. F., Mehra, N., Somford, D. M., Bergman, A. M., Ten Bokkel Huinink, D., Fossion, L., Geenen, M. M., Hendriks, M. P., van de Luijtgaarden, A. C. M., Polee, M. B., Weijl, N. I., van de Wouw, A. J., de Wit, R., Uyl-de Groot, C. A., & Gerritsen, W. R. (2021). Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. European urology oncology, 4(4), 618-627. https://doi.org/10.1016/j.euo.2019.09.005
Kuppen, Malou C P, et al. "Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry." European urology oncology vol. 4,4 (2021): 618-627. doi: https://doi.org/10.1016/j.euo.2019.09.005
Kuppen MCP, Westgeest HM, van den Eertwegh AJM, van Moorselaar RJA, van Oort IM, Coenen JLLM, van den Bergh ACMF, Mehra N, Somford DM, Bergman AM, Ten Bokkel Huinink D, Fossion L, Geenen MM, Hendriks MP, van de Luijtgaarden ACM, Polee MB, Weijl NI, van de Wouw AJ, de Wit R, Uyl-de Groot CA, Gerritsen WR. Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. Eur Urol Oncol. 2021 Aug;4(4):618-627. doi: 10.1016/j.euo.2019.09.005. Epub 2019 Oct 08. PMID: 31601523.
Copy Download .nbib Format: NLM
[At the retirement of Prof. Dr. E. Gorter from Leiden University].

Nederlands tijdschrift voor geneeskunde

TEN BOKKEL HUININK A.
PMID: 14919770
Ned Tijdschr Geneeskd. 1951 Dec 29;95(52):3910-2.

No abstract available.

Cite
TEN BOKKEL HUININK A. Bij het afscheid van Prof. Dr. E. Gorter als hoogleraar te Leiden. [At the retirement of Prof. Dr. E. Gorter from Leiden University]. Ned Tijdschr Geneeskd. 1951;95(52):3910-2
TEN BOKKEL HUININK, A. (1951). Bij het afscheid van Prof. Dr. E. Gorter als hoogleraar te Leiden. [At the retirement of Prof. Dr. E. Gorter from Leiden University]. Nederlands tijdschrift voor geneeskunde, 95(52), 3910-2.
TEN BOKKEL HUININK, A. "Bij het afscheid van Prof. Dr. E. Gorter als hoogleraar te Leiden." [At the retirement of Prof. Dr. E. Gorter from Leiden University]. Nederlands tijdschrift voor geneeskunde vol. 95,52 (1951): 3910-2.
TEN BOKKEL HUININK A. Bij het afscheid van Prof. Dr. E. Gorter als hoogleraar te Leiden. [At the retirement of Prof. Dr. E. Gorter from Leiden University]. Ned Tijdschr Geneeskd. 1951 Dec 29;95(52):3910-2. Undetermined. PMID: 14919770.
Copy Download .nbib Format: NLM
Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens.

Clinical drug investigation

Nannan Panday VR, van Warmerdam LJ, Huizing MT, Ten Bokkel Huinink WW, Vermorken JB, Giaccone G, Veenhof CH, Schellens JH, Beijnen JH.
PMID: 18370488
Clin Drug Investig. 1998;15(4):327-35. doi: 10.2165/00044011-199815040-00009.

Carboplatin is a frequently used antitumour agent recommended to be administered according to the Calvert formula: dose = AUC x (GFR+25), where GFR is the glomerular filtration rate as measured by (51)Cr-EDTA clearance and AUC is the targeted area...

Cite
Nannan Panday VR, van Warmerdam LJ, Huizing MT, et al. Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens. Clin Drug Investig. 1998;15(4):327-35doi: 10.2165/00044011-199815040-00009.
Nannan Panday, V. R., van Warmerdam, L. J., Huizing, M. T., Ten Bokkel Huinink, W. W., Vermorken, J. B., Giaccone, G., Veenhof, C. H., Schellens, J. H., & Beijnen, J. H. (1998). Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens. Clinical drug investigation, 15(4), 327-35. https://doi.org/10.2165/00044011-199815040-00009
Nannan Panday, V R, et al. "Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens." Clinical drug investigation vol. 15,4 (1998): 327-35. doi: https://doi.org/10.2165/00044011-199815040-00009
Nannan Panday VR, van Warmerdam LJ, Huizing MT, Ten Bokkel Huinink WW, Vermorken JB, Giaccone G, Veenhof CH, Schellens JH, Beijnen JH. Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens. Clin Drug Investig. 1998;15(4):327-35. doi: 10.2165/00044011-199815040-00009. PMID: 18370488.
Copy Download .nbib Format: NLM
[Annual medical meeting at the Brousais Hospital].

Nederlands tijdschrift voor geneeskunde

TEN BOKKEL HUNINK SA.
PMID: 13013422
Ned Tijdschr Geneeskd. 1952 Sep 20;96(38):2376-7.

No abstract available.

Cite
TEN BOKKEL HUNINK SA. Les journées médicales de l'Hôpital Broussais. [Annual medical meeting at the Brousais Hospital]. Ned Tijdschr Geneeskd. 1952;96(38):2376-7
TEN BOKKEL HUNINK, S. A. (1952). Les journées médicales de l'Hôpital Broussais. [Annual medical meeting at the Brousais Hospital]. Nederlands tijdschrift voor geneeskunde, 96(38), 2376-7.
TEN BOKKEL HUNINK, S A. "Les journées médicales de l'Hôpital Broussais." [Annual medical meeting at the Brousais Hospital]. Nederlands tijdschrift voor geneeskunde vol. 96,38 (1952): 2376-7.
TEN BOKKEL HUNINK SA. Les journées médicales de l'Hôpital Broussais. [Annual medical meeting at the Brousais Hospital]. Ned Tijdschr Geneeskd. 1952 Sep 20;96(38):2376-7. Undetermined. PMID: 13013422.
Copy Download .nbib Format: NLM
Showing 1 to 7 of 7 entries